Insulet Corp. PODD

What this company does

Insulet Corporation develops, manufactures, and sells continuous insulin delivery systems for people with insulin-dependent diabetes, including the Omnipod 5 Automated Insulin Delivery System, the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system intended to help reduce the risk of infection after intense chemotherapy. It sells Omnipod products to wholesalers that supply the pharmacy channel in the United States, and through distribution partners and directly to consumers in other markets. It manufactures its products at two automated facilities in Acton, Massachusetts, and Johor, Malaysia, is investing in a third manufacturing plant in Costa Rica, and also produces devices on manufacturing lines at a facility in China operated by a contract manufacturer. As of December 31, 2025, Insulet had approximately 5,400 full-time employees, a 38% increase over the prior year, with about 60% located in the United States and the remainder in 17 other countries. Insulet Corporation is a Delaware corporation formed in 2000.

Written from the business description in INSULET CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 18 February 2026. Every sentence was checked against that document before publication.